share_log
Reuters ·  Mar 18 13:30
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (Aminolevulinic Acid Hci) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 242

Recommended

Write a comment